Emyria to plug $2.5M into depression treatment program at Empax Centre

Emyria Ltd (ASX:EMD) is raising more than two and a half million dollars to facilitate expansion of the mental health treatment services offered at its ‘Empax Centre’ in Perth with a placement supported by sophisticated and professional investors.

The company has received firm commitments from the latter for the placement, with shares priced at 3.5 cents for a total raise of $2.525 million.

Within this, chairman Greg Hutchinson contributed a cornerstone subscription of $1 million.

Among the services to be expanded at the Empax Centre – which opened in April – is a treatment-resistant depression program for which Emyria has recently received approval.

Chairman Greg Hutchinson said the development of such a program was timely.

“Australia’s mental health crisis is escalating rapidly, underscoring the urgent need for more effective solutions,” he said.

“As a leader in world-class mental health programs, Emyria is uniquely positioned, and obligated, to address this challenge.

“As the only ASX-listed company delivering direct care in this field, our mission is clear: to expand access to our innovative treatments, improving the lives of more Australians.”

Emyria shares have shifted upwards today, and at 12:58 AEDT, they were trading at 4 cents – a rise of 2.56% since the market opened.

Join the discussion: See what HotCopper users are saying about Emyria and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.